Critical Illness Polyneuropathy: Causes, Symptoms, & Recovery

Critical illness polyneuropathy (CIP) is a form of nerve damage that develops in people who are severely ill and hospitalized in an intensive care unit, typically after sepsis, multi-organ failure, or prolonged mechanical ventilation. It causes symmetrical, predominantly distal weakness and sensory loss driven by damage to the axons of peripheral nerves rather than their protective coating.¹ The condition is a major reason patients struggle to be weaned off ventilators, and recovery varies widely, with some people regaining full function and others living with lasting disability.

What Happens to the Nerves

CIP is classified as an axonal polyneuropathy, meaning the damage targets the long fiber of the nerve cell rather than the myelin sheath that insulates it. Both motor nerves (controlling movement) and sensory nerves (carrying sensation) are affected. Because the axon itself degenerates, recovery depends on regrowth of nerve fibers, which is a slow biological process measured in months rather than weeks.

The underlying trigger is systemic inflammation. When the body mounts an overwhelming immune response to infection or injury, inflammatory molecules and microvascular changes compromise blood flow to peripheral nerves. The nerves in the limbs, which have the longest axons, are most vulnerable. This is why weakness and numbness tend to be worst in the hands and feet and more pronounced in the legs than the arms. Facial nerves are usually spared.

CIP frequently coexists with critical illness myopathy (CIM), a separate condition that damages muscle fibers directly. Many patients have both at once, a combination sometimes called critical illness polyneuromyopathy.² Distinguishing between the two matters for prognosis, because pure myopathy tends to recover more completely than polyneuropathy.

Causes and Risk Factors

Sepsis is the single most important risk factor. The intense, body-wide inflammatory cascade of sepsis creates the microvascular dysfunction that starves peripheral nerves of oxygen and nutrients. Multi-organ dysfunction amplifies the damage. Beyond sepsis itself, several ICU-related factors raise the likelihood of developing CIP:

Hyperglycemia: Stress-related high blood sugar is strongly linked to CIP. In critically ill patients, elevated glucose appears to worsen nerve damage through oxidative stress and impaired microcirculation.³ A study comparing patients whose blood sugar was kept tighter (averaging around 132 mg/dL) versus those with higher levels (averaging around 170 mg/dL) found that CIP was diagnosed significantly less often in the lower-glucose group, and those patients also spent less time on mechanical ventilation.⁴
Prolonged mechanical ventilation: The longer someone is on a ventilator, the greater the risk. Immobility compounds the nerve and muscle damage already under way.
Duration and severity of critical illness: Higher illness-severity scores and longer ICU stays consistently predict CIP in observational studies.

For years, corticosteroids and neuromuscular blocking agents administered in the ICU were suspected of contributing to CIP. Early case reports painted a worrying picture. But a historical review of the literature found that as data quality improved over the decades, the link between these drugs and ICU-acquired weakness weakened substantially. Changes in clinical practice, including lower steroid doses, the switch to newer neuromuscular blockers, and better blood sugar control, may explain the shift. Based on the best available evidence, neither corticosteroids at commonly used doses nor modern neuromuscular blockers appear to independently increase the duration of mechanical ventilation, which is the most consequential outcome of weakness in the ICU.⁵ That said, older literature and some clinicians still associate high-dose steroids and prolonged paralytic infusions with myopathy specifically.⁶

What CIP Looks and Feels Like

The hallmark of CIP is flaccid, symmetrical weakness that is worse further from the trunk. Reflexes are reduced or absent, and sensation in the feet and lower legs is diminished. In the ICU, these signs are often masked by sedation, delirium, or the patient’s overall critical state. The most common way CIP announces itself clinically is when a patient who is otherwise recovering from their acute illness cannot be weaned from the ventilator.⁷ The respiratory muscles, particularly the diaphragm, rely on long motor nerves that are susceptible to the same axonal damage affecting the limbs.

Once patients are awake and cooperative enough to be examined, the picture becomes clearer. They may be unable to lift their arms against gravity, grip objects firmly, or stand. Sensory complaints like tingling, numbness, or a burning sensation in the extremities sometimes surface, though many ICU patients are too sick to report these reliably. Unlike conditions such as Guillain-Barré syndrome, CIP does not typically cause autonomic instability (wild swings in heart rate or blood pressure) on its own, which helps clinicians narrow down the cause.

How CIP Is Diagnosed

Diagnosing CIP in a busy ICU is genuinely difficult. The patient is often sedated, possibly delirious, and attached to multiple lines and devices. Physical examination has obvious limitations when someone cannot follow commands. Clinicians rely on a combination of clinical suspicion, exclusion of other causes, and electrophysiological testing.

A definite diagnosis requires three things: the critically ill patient develops limb weakness or difficulty weaning after non-neuromuscular causes like heart or lung disease have been excluded; nerve conduction studies and electromyography show an axonal motor and sensory polyneuropathy; and repetitive nerve stimulation does not produce a decremental response, which would suggest a neuromuscular junction problem instead.⁸ In practice, getting high-quality nerve conduction studies at the bedside is tricky. Electrical interference from surrounding equipment, tissue edema from fluid resuscitation, and cool skin temperature can all degrade the results.

When electrophysiology is ambiguous or unavailable, clinicians sometimes perform direct muscle stimulation to differentiate between nerve and muscle problems. In CIP, the muscle itself responds normally to direct electrical stimulation because the damage is in the nerve; in myopathy, the muscle’s direct response is also abnormal. Muscle biopsy remains a definitive way to confirm myopathy but is rarely done solely for this purpose given its invasiveness.

Blood Biomarkers on the Horizon

One of the frustrations with CIP is that diagnosis depends on specialized neurophysiological testing that is hard to perform early, exactly when identifying the problem would be most useful. Researchers have been hunting for blood-based markers that could flag nerve damage sooner.

Neurofilament light chain (NfL) is the most promising candidate. NfL is a structural protein released into the bloodstream when axons are damaged. In a study of ICU patients, those who went on to develop CIP had significantly higher NfL levels at admission compared to those who did not, with median values roughly fifteen times higher in affected patients.⁹ A separate prospective study in COVID-19 patients confirmed this pattern and also found elevated glial fibrillary acidic protein (GFAp), another marker of nervous system injury, in patients who later developed CIP or CIM. Both biomarkers were elevated early in the ICU stay, before clinical or electrophysiological signs appeared.¹⁰

These biomarkers are not yet part of routine clinical practice. Their values overlap between conditions and vary with the severity of the underlying illness, so they cannot replace electrophysiology. But if validated in larger studies, they could help identify high-risk patients early enough to intensify preventive measures.

What Can Be Done to Prevent It

There is no drug that prevents or cures CIP. Prevention revolves around managing the modifiable risk factors during the ICU stay, and two strategies have the strongest evidence behind them: early mobilization and glucose control.

Getting critically ill patients moving as early as safely possible, even something as basic as sitting up in bed or passive range-of-motion exercises, has been shown to be safe and feasible. Research consistently links early mobilization to improved physical function, shorter time on the ventilator, and shorter ICU and hospital stays.¹¹ One study found that early mobilization and tighter insulin-driven glucose control each independently reduced the odds of developing ICU-acquired weakness, even after accounting for other known risk factors.¹²

Nutrition also plays a role. Muscle wasting begins within days of ICU admission due to inflammation, immobility, and catabolic hormones. Higher-protein feeding during the first week of ICU care has been shown to reduce muscle wasting compared to standard nutritional formulas.¹³ A meta-analysis of protein supplementation in critically ill patients found that higher protein intakes were associated with a small but meaningful improvement in skeletal muscle strength.¹⁴ While these nutrition studies focus on muscle preservation rather than nerve protection per se, maintaining muscle mass helps compensate for weak nerve signals during recovery.

Recovery and Long-Term Outlook

Recovery from CIP is slower and less complete than recovery from critical illness myopathy. In a study that followed patients for a year after ICU discharge, the difference was stark: roughly nine out of ten patients with pure myopathy had recovered, compared with just over half of those who had the combination of myopathy and polyneuropathy. More than a third of the combined group still needed help with daily activities a full year later.¹⁵ The reason for the gap traces back to what is damaged: muscle fibers regenerate relatively efficiently, while axon regrowth is measured in millimeters per day and must span long distances to reconnect with target muscles.

Even among patients who do recover strength, the broader picture of functioning is often still impaired at twelve months. A study of functional outcomes found that while physical capacity improved in all CIP patients over the first year, activities related to outdoor mobility, independence, social participation, and overall quality of life remained restricted for most.¹⁶ The physical weakness interacts with the cognitive, psychological, and functional consequences of prolonged critical illness, sometimes grouped under the umbrella of post-intensive care syndrome. Anabolic resistance, impaired muscle regeneration, and mitochondrial dysfunction in surviving muscle tissue can persist well beyond the ICU, contributing to lasting fatigue and exercise intolerance.

Rehabilitation after discharge is essential but often fragmented. Patients may transition from ICU to a step-down ward, then to inpatient rehabilitation, then to outpatient therapy, sometimes with gaps at each handoff. The lack of a single specialist “owning” follow-up for ICU-acquired weakness means that CIP can get lost among the patient’s many competing medical problems. Physiotherapy remains the cornerstone of recovery: progressive resistance training, gait retraining, and endurance work tailored to what the patient can tolerate.

Measuring Recovery Beyond Muscle Strength

Clinicians increasingly recognize that grip strength or the ability to stand does not capture the full impact of CIP on a person’s life. Patient-reported outcome tools that measure disability, daily functioning, and perceived health have been tested in ICU survivors. One study found that a broad disability questionnaire correlated strongly with physical performance tests like walking distance and functional independence, though it correlated only moderately with grip strength.¹⁷ The gap between what a patient can do in a controlled test and how they actually function at home underscores why follow-up should ask patients about their real-world limitations, not just measure isolated muscle groups.

CIP in Children

CIP is overwhelmingly described in adults, but it does occur in children. Pediatric ICU patients face many of the same risk factors: sepsis, multi-organ dysfunction, prolonged ventilation, and high blood sugar. A study of mechanically ventilated children found that about a third who were awake enough to be assessed met electrophysiological criteria for CIP or CIM, predominantly in an axonal polyneuropathy pattern. Weaning failure was common in this group, and the condition was associated with low platelets, elevated liver enzymes, low albumin, acidosis, and higher blood glucose, many of the same metabolic derangements seen in adults.¹⁸

However, a prospective study that used simplified serial nerve testing in nearly 100 children with a median age of seven found no significant nerve amplitude drops over the course of the ICU stay, despite the cohort having high rates of sepsis and organ support.¹⁹ The conflicting results likely reflect differences in study populations, illness severity, and diagnostic methods. The honest answer is that CIP in children is underrecognized and understudied. Young patients who are weak after a critical illness often get better quickly enough that the question of CIP is never formally investigated, which leaves real uncertainty about how common it truly is in this age group.

Experimental Neuroprotective Approaches

Because no approved drug treats CIP, animal research has explored whether agents that reduce inflammation and oxidative stress could protect peripheral nerves during sepsis. In a rat model, both melatonin and oxytocin reversed the electrophysiological signs of nerve damage caused by experimentally induced sepsis. Both agents suppressed oxidative stress markers and tumor necrosis factor alpha (TNF-α), a central inflammatory molecule.²⁰ Memantine, a drug used in Alzheimer’s disease, has also been evaluated in a sepsis rat model for its potential to limit CIP through anti-inflammatory and antioxidant pathways.²¹

None of these findings have moved into human trials for CIP specifically. The gap between promising rodent data and proven human therapies is wide across all of neurology, and CIP poses additional challenges: the patients are heterogeneous, extremely sick, and often enrolled in other trials simultaneously. For now, the practical takeaway is that neuroprotection in CIP remains an idea being tested in laboratories, not a treatment available at the bedside. The strategies that do help, getting patients moving early, controlling blood sugar, and providing adequate protein, are decidedly unglamorous but supported by clinical evidence in humans.